SCHEMBL1329600

SCHEMBL1329600

O=[N+]([O-])c1ncccc1Sc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
LMNA P02545 5/20 0.56
GAA P10253 3/20 0.56
THRB P10828 1/20 0.56
MAPT P10636 7/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
ALDH1A1 P00352 4/20 0.50
HPGD P15428 2/20 0.50
GSTP1 P09211 1/20 0.46
GSTM2 P28161 1/20 0.46
PDE7A Q13946 2/20 0.45
PDE7B Q9NP56 1/20 0.45
NPSR1 Q6W5P4 2/20 0.40
CYP19A1 P11511 1/20 0.40
HTT P42858 1/20 0.40
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1330570 0.87 MAPT (0.52) MEN1KMT2ALMNAGAATHRB
SCHEMBL15691347 0.81 MAPT (0.44) MEN1KMT2ALMNAGAATHRB
SCHEMBL1137437 0.80 MAPT (0.43) MEN1KMT2ALMNAGAATHRB
SCHEMBL1329695 0.78 KMT2A (0.59) MEN1KMT2ALMNAGAATHRB
SCHEMBL24930524 0.77 L3MBTL1 (0.47) MEN1KMT2ALMNAGAATHRB
SCHEMBL21802324 0.77 MAPT (0.41) MEN1KMT2ALMNAGAATHRB
SCHEMBL30911319 0.77 MAPT (0.41) MEN1KMT2ALMNAGAATHRB
SCHEMBL30586325 0.77 L3MBTL1 (0.47) MEN1KMT2ALMNAGAATHRB
SCHEMBL8562802 0.76 MEN1 (0.61) MEN1KMT2ALMNAGAATHRB
SCHEMBL5522366 0.74 SIRT1 (0.44) MEN1KMT2ALMNAGAATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013204-B1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2015-02-18 EP disclosed
EP-2543667-B1 A method of preparing 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC (US) 2015-01-28 EP disclosed
US-8883828-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2014-11-11 US disclosed
EP-2543667-A9 2-aminopyridine analogs as glucokinase activators Array Biopharma, Inc. (US) 2013-08-21 EP disclosed
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2013-03-14 US disclosed
US-8362037-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2013-01-29 US disclosed
US-8354540-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2013-01-15 US disclosed
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2011-11-17 US disclosed
US-8022223-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 US disclosed
EP-2173745-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2010-04-14 EP disclosed
CN-101679405-A 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC 2010-03-24 CN disclosed
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-06-18 US disclosed
WO-2008118718-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2008-10-02 WO disclosed
WO-2007117381-A9 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 MEN1 4229/4885KMT2A 1406/4885LMNA 4132/4885
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, PRKCSH MEN1 1943/4885KMT2A 1093/4885LMNA 4096/4885
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 MEN1 4229/4885KMT2A 1406/4885LMNA 4132/4885
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 MEN1 4229/4885KMT2A 1406/4885LMNA 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.